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Fractalkine-CX3CR1 signaling is 
critical for progesterone-mediated 
neuroprotection in the retina
Sarah L. Roche, Alice C. Wyse-Jackson, Ana M. Ruiz-Lopez, Ashleigh M. Byrne & 
Thomas G. Cotter
Retinitis pigmentosa (RP) encompasses a group of retinal diseases resulting in photoreceptor loss 
and blindness. We have previously shown in the rd10 mouse model of RP, that rd10 microglia drive 
degeneration of viable neurons. Norgestrel, a progesterone analogue, primes viable neurons against 
potential microglial damage. In the current study we wished to investigate this neuroprotective effect 
further. We were particularly interested in the role of fractalkine-CX3CR1 signaling, previously shown 
to mediate photoreceptor-microglia crosstalk and promote survival in the rd10 retina. Norgestrel 
upregulates fractalkine-CX3CR1 signaling in the rd10 retina, coinciding with photoreceptor survival. 
We show that Norgestrel-treated photoreceptor-like cells, 661Ws, and C57 explants modulate 
rd10 microglial activity in co-culture, resulting in increased photoreceptor survival. Assessment of 
Norgestrel’s neuroprotective effects when fractalkine was knocked-down in 661 W cells and release 
of fractalkine was reduced in rd10 explants confirms a crucial role for fractalkine-CX3CR1 signaling in 
Norgestrel-mediated neuroprotection. To further understand the role of fractalkine in neuroprotection, 
we assessed the release of 40 cytokines in fractalkine-treated rd10 microglia and explants. In both 
cases, treatment with fractalkine reduced a variety of pro-inflammatory cytokines. These findings 
further our understanding of Norgestrel’s neuroprotective properties, capable of modulating harmful 
microglial activity indirectly through photoreceptors, leading to increased neuroprotection.
Retinitis pigmentosa (RP) encompasses a set of hereditary diseases resulting in a progressive loss of rod and 
subsequently cone photoreceptors, leading to eventual blindness. The rd10 mouse model of RP harbors a muta-
tion in phosphodiesterase-6b (pde6b) and is widely used to study retinal degeneration and investigate potential 
therapeutics for RP. Although microglia are essential in the clearance of cell debris during degeneration in the 
CNS1–3, recent publications have suggested a detrimental role for microglia in the retina, as drivers of retinal 
degeneration4–8. Previous studies therefore propose that microglia are not merely bystander cells during retinal 
degeneration but are actively contributing to disease progression. Hence, microglia represent a potential thera-
peutic target for the treatment of retinal degeneration. Indeed, genetic and pharmaceutical targeting of microglial 
activity in the diseased retina is effective in promoting photoreceptor cell survival5–7,9–11.
Our group has previously reported on the neuroprotective properties of Norgestrel in the retina7,12–16. In such 
studies we have used a photoreceptor-like cell line, 661 W, to study the stress response of photoreceptors and 
reveal the signaling pathways leading to Norgestrel-mediated neuroprotection7,13,14,17. We have previously shown 
that isolated rd10 microglia drive degeneration of 661 W cells in vitro and that pre-treating 661 W cells with 
Norgestrel alleviates microglial-driven degeneration7. Thus, Norgestrel revealed a principal aspect of its neuro-
protective properties; through the modulation of photoreceptor-microglia crosstalk.
Fractalkine (CX3CL1) is a chemokine synthesized as a 50–75 kDa protein18. It is glycosylated forming a trans-
membrane 100 kDa protein18–20. Membrane-bound fractalkine consists of a chemokine domain with CX3 C 
motif, a highly-glycosylated mucin-like stalk, a transmembrane domain and a short cytoplasmic domain21. 
Membrane-bound fractalkine is cleaved by endogenous metalloproteinases, predominantly ADAM10, to release 
soluble fractalkine (85 kDa)22. Fractalkine can be recycled from the membrane and stored in intracellular vesi-
cles19,20. In the retina, fractalkine’s sole receptor, CX3CR1, is present on microglia23. Fractalkine-CX3CR1 signal-
ing provides a means of intercellular signaling between neurons and microglia in the retina.
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In the rd10 mouse, we found that Norgestrel upregulated fractalkine-CX3CR1 signaling 1000 fold at the 
RNA level, during significant protection of photoreceptors7. Studies have documented a neuroprotective role for 
fractalkine-CX3CR1 signaling in the rd10 retina. Although fractalkine is constitutively expressed in the retina 
throughout postnatal development19, retinal development is unaffected by the absence of fractalkine-CX3CR1 
signaling24. However, with the onset of stressful stimuli, such as downstream effects of the mutation in the rd10 
retina, absence of fractalkine signaling results in increased microglial infiltration and phagocytosis of photo-
receptors, potentiating disease progression6,9. Intra-vitreal injection of recombinant fractalkine reduces micro-
glial infiltration, phagocytosis and photoreceptor cell death in the rd10 retina9. Previous work thus hints at the 
involvement of fractalkine-CX3CR1 signaling in Norgestrel-mediated neuroprotection. In the current study, we 
investigated the role of fractalkine-CX3CR1 signaling in Norgestrel-dependent neuroprotection.
Using a co-culture of C57 explants and rd10 microglia we expand on previous observations to show that 
rd10 microglia drive degeneration of viable photoreceptors ex vivo, as well as 661 W cells in vitro. Photoreceptor 
cell death is abrogated by pre-treating 661 W cells and explants with Norgestrel. Norgestrel-mediated protec-
tion is accompanied by less microglial association with 661 W cells and photoreceptors in vitro and ex vivo. 
Hypothesizing that fractalkine-CX3CR1 signaling plays a crucial role, we show that fractalkine is upregulated 
in 661 W cells and C57 explants with Norgestrel. Knockdown of fractalkine in 661 W cells by siRNA confirms 
that Norgestrel utilizes fractalkine-CX3CR1 signaling to protect 661 W cells from microglial-derived damage. 
Using an inhibitor of ADAM10 to manipulate the cleavage of fractalkine, we confirm in rd10 explants that the 
release of soluble fractalkine is critical to Norgestrel-dependent neuroprotection. In addition to induction of a 
migratory phenotype, we show that soluble fractalkine modulates cytokine release in isolated rd10 microglia 
and rd10 explants. Taken together, these findings highlight a critical role for fractalkine-CX3CR1 signaling in 
Norgestrel-dependent neuroprotection and further our understanding of the role of fractalkine in regulating 
microglial activity in the retina.
Results
Norgestrel primes viable cells against potential microglial-derived toxicity. As previously 
described7, co-culturing 661 W cells with P15 rd10 microglia for 24hr resulted in a significant increase in 
661 W cell death compared to co-culturing with C57 microglia, as assessed by TUNEL (Fig. 1A,B). As expected, 
pre-treating 661 W cells with 20 μ M Norgestrel for 24 hr before co-culture, significantly reduced microglial-driven 
degeneration7 (Fig. 1A,B). In order to determine if photoreceptors responded in a similar way in the retina, we 
Figure 1. Norgestrel primes viable cells against microglial-derived toxicity. (A) Quantification of TUNEL+ 
661 W cells pre-treated with 20 μ M Norgestrel or vehicle (DMSO) and in co-culture with C57 or rd10 microglia 
(N = 8 mice for primary culture, n = 6 technical replicates). (B) Example images of TUNEL+ 661 W cells 
(green) in co-culture with microglia. Scale bar 30 μ m. (C) Quantification of TUNEL fluorescence intensity in 
P20 C57 explants treated with Norgestrel or vehicle and in co-culture with rd10 microglia (N = 3 explants, n = 4 
technical replicates). (D) Example images of TUNEL reactivity (green) in the ONL of P20 C57 explants treated 
with Norgestrel or vehicle and in co-culture with rd10 microglia. Scale bar 50 μ m. Hoechst reveals cell nuclei. 
Results are presented as mean ± SEM (t-test, **p < 0.01, ****p < 0.0001).
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co-cultured P20 C57 retinal explants with rd10 microglia for 19hr. Similar to our observations with 661 W cells, 
we show that rd10 microglia kill viable photoreceptors ex vivo (Fig. 1C,D). Pre-treating C57 explants with 20 μ M 
Norgestrel for 5 hr prior to co-culture with rd10 microglia, significantly reduced microglial-driven degeneration 
(Fig. 1C,D).
Norgestrel-treated photoreceptors modulate microglial migration. We wished to understand 
Norgestrel’s neuroprotective mechanism regulating photoreceptor-microglial crosstalk. Firstly, by quantifying 
the number of 661 W cells in direct contact with rd10 microglia in co-culture, we show that significantly less 
661Ws were contacted by microglia when pre-treated with 20 μ M Norgestrel for 24 hr (Fig. 2A,C). The average 
number of microglia contacting 661 W cells was also significantly less in the Norgestrel-treated group (Fig. 2B,C). 
As expected in an untreated C57 P20 explant25, we observed microglia situated in the outer plexiform layer (OPL) 
but not in the outer nuclear layer (ONL) (Fig. 2D,E). In the DMSO-treated C57 explant cultured with rd10 micro-
glia, there was a significant increase in the number of microglia in the ONL, OPL and outer segment layer (OSL) 
collectively (Fig. 2E). Microglia could be seen infiltrating the retina from both the outer and inner retinal surfaces 
(Fig. 2D; explant DMSO + rd10 microg.). When C57 explants were pre-treated with Norgestrel prior to co-culture 
Figure 2. Norgestrel-treated 661 W cells and C57 photoreceptors modulate microglial migration. (A) 
Quantification of the number of 661 W cells pre-treated with 20 μ M Norgestrel or vehicle (DMSO) contacted 
by rd10 microglia. (B) Quantification of the average number of microglia contacting 661 W cells in (A) (N = 8 
mice for primary culture, n = 6 technical replicates). (C) Example images of 661 W cells (Cone Arrestin; red) 
pre-treated with Norgestrel or vehicle in co-culture with rd10 microglia. Scale bar 30 μ m. (D) Example images 
of microglia (Iba1; red) and activated microglia (CD68; green) in untreated P20 C57 explants, and explants 
treated with Norgestrel or vehicle and in co-culture with rd10 microglia. Scale bar 50 μ m. (E) Quantification 
of the number of microglia situated in the outer plexiform layer (OPL), outer nuclear layer (ONL) and outer 
segment layer (OSL) collectively, in untreated P20 C57 explants, and explants treated with Norgestrel or vehicle 
and in co-culture with rd10 microglia (N = 3 explants, n = 4 technical replicates). Hoechst reveals cell nuclei. 
Results are presented as mean ± SEM (t-test, *p < 0.05, **p < 0.01, ***p < 0.005).
www.nature.com/scientificreports/
4Scientific RepoRts | 7:43067 | DOI: 10.1038/srep43067
with rd10 microglia, there was a significant decrease in the number of microglia situated in the OPL, ONL and 
OSL (Fig. 2D,E). We therefore hypothesized that Norgestrel was modulating microglial activity indirectly through 
photoreceptors, by altering the release of chemotactic cytokines from photoreceptors, destined for microglia.
Norgestrel upregulates fractalkine in vivo and ex vivo. Fractalkine is a chemotactic cytokine 
expressed by neurons. In the retina, its sole receptor CX3CR1 is found on microglia23 providing an intercellular 
signaling mechanism between photoreceptors and microglia. We have previously shown that Norgestrel upregu-
lates fractalkine-CX3CR1 signaling in rd10 mice during a time of significant preservation of the ONL7. It has also 
been shown that fractalkine-CX3CR1 signaling is neuroprotective in the rd10 retina6,9. Based on these findings 
we hypothesized that Norgestrel was modulating microglial activity indirectly through an upregulation of frac-
talkine signaling from photoreceptors, consequently providing neuroprotection. To test this hypothesis, we firstly 
assessed changes in fractalkine levels in cells treated with Norgestrel.
661 W cells treated with 20 μ M Norgestrel for 24 hr showed a significant increase in fractalkine as measured 
by immunofluorescence (Fig. 3A,B). Western blotting confirmed an increase in membrane-bound fractalkine 
(Fig. 3C,D; 100 kDa). Soluble fractalkine was not observed by Western blot as this would have been released in to 
the media. Treatment of C57 P20 explants with 20 μ M Norgestrel over 5 hr also revealed a significant increase in 
fractalkine by immunofluorescence (Fig. 3E,F). Both membrane-bound and soluble fractalkine were upregulated 
as determined by Western blotting (Fig. 3G,H; 100 kDa and 85 kDa). An increase in a band at 95 kDa was also 
observed with Norgestrel treatment in 661 W cells and C57 explants. This band likely represents an intra-vesicular 
store of fractalkine that is destined for or has been recycled from the membrane19,20. Analysis of CX3CR1 by 
Western blot revealed no change following treatment with Norgestrel (Fig. 3G,H; blue box). These results suggest 
that Norgestrel utilizes fractalkine-CX3CR1 signaling to protect viable photoreceptors against potential micro-
glial damage.
Fractalkine signaling is required for Norgestrel-mediated neuroprotection. In order to deter-
mine if fractalkine-CX3CR1 signaling is essential for Norgestrel’s neuroprotective effects, we targeted frac-
talkine expression with siRNA in 661 W cells. Knockdown of fractalkine was achieved over 72 hr as evidenced 
by a substantial loss at the protein level (Fig. 4A,B) and RNA level (Fig. 4C). Importantly, neither transfection 
with scrambled RNA nor fractalkine siRNA affected 661 W cell viability as compared to untreated 661 W cells 
(Fig. 4D). 661 W cells treated with scrambled or siRNA fractalkine over 72 hr were subsequently treated with 
20 μ M Norgestrel or vehicle for 24 hr and co-cultured with rd10 microglia for a further 24 hr. As expected, 
Norgestrel-treated 661 W cells were significantly protected against microglial damage as assessed by TUNEL 
(Fig. 4E,F; scrambled). When fractalkine levels were reduced with targeted siRNA, Norgestrel’s protective effects 
were abrogated (Fig. 4E,F; scrambled NORG vs siRNA fract. NORG). We next sought to evaluate the contribu-
tion of fractalkine-CX3CR1 signaling to Norgestrel’s neuroprotective effects in the rd10 retina. As described in 
previous sections, membrane-bound fractalkine is cleaved to form soluble fractalkine that is released from the 
cell membrane. ADAM10 has been described as the metalloproteinase largely responsible for this cleavage22,26. 
Using a potent inhibitor of ADAM10, GI254023X, we assessed Norgestrel’s neuroprotective effects ex vivo 
when fractalkine cleavage was reduced. GI254023X (Inhibitor/INH.) was effective in reducing levels of soluble 
fractalkine in rd10 P15 retinal explants over 24 hr (Fig. 5A,B; DMSO vs INH 85 kDa, green box). Treatment of 
explants with Norgestrel resulted in an increase in membrane-bound fractalkine (Fig. 5A,B; 100 kDa, red box). 
Levels of CX3CR1, the receptor for fractalkine, remained unchanged following treatment with Norgestrel and/
or ADAM10 inhibitor (Fig. 5A,B; blue box). We show that inhibiting the cleavage of fractalkine in rd10 P15 
explants results in exacerbated photoreceptor cell death; indicated by a 29% increase in TUNEL compared to 
vehicle (Fig. 5C,D). This supports previous findings of a neuroprotective role for fractalkine signaling in the rd10 
retina6,9. As expected, Norgestrel provided significant protection to rd10 retinal explants, as evident by a 30% 
decrease in TUNEL compared to DMSO (Fig. 5C,D). However, when fractalkine cleavage was inhibited in the 
presence of Norgestrel, TUNEL increased and was similar to levels observed with inhibitor alone (Fig. 5C,D). 
Norgestrel therefore requires fractalkine-CX3CR1 signaling to generate its neuroprotective effects in the retina.
Soluble fractalkine induces a migratory phenotype and reduces inflammatory cytokine production 
in rd10 microglia. Confirmation of a critical role for fractalkine-CX3CR1 signaling in the neuroprotective 
properties of Norgestrel prompted us to investigate the effects of soluble fractalkine on microglial activity and 
photoreceptor survival. In support of other studies, we show that administration of recombinant fractalkine to 
P15 rd10 retinal explants for 24 hr is neuroprotective (Fig. 6A,B)9. As expected based on previous observations25, 
microglia were located in close association with clusters of photoreceptors in the rd10 retina at P15 and were 
positive for phagocytic markers (CD68) (Fig. 6C,D). Following treatment with soluble fractalkine, numbers of 
microglia in the P15 rd10 ONL decreased significantly (Fig. 6C,D). Microglia appeared to migrate away from the 
ONL and were mainly observed in the inner nuclear layer (INL) and retinal ganglion cell (RGC) layer (Fig. 6C). 
These microglia presented a more scavenging, migratory phenotype with less CD68 immunoreactivity, compared 
to vehicle (Fig. 6C).
Microglia release a variety of pro-inflammatory cytokines, which could contribute to disease progres-
sion in the retina5,11,27–31. We therefore investigated the effects of fractalkine on cytokine production in rd10 
retinal explants and isolated rd10 microglia to further our understanding of the role of fractalkine release in 
Norgestrel-driven neuroprotection. Using a proteome profiler kit designed to detect a variety of 40 cytokines, 
we assessed cytokine production in rd10 P15 retinal explants treated with soluble fractalkine for 24 hr. This 
revealed that cytokine production was altered in rd10 retinal explants as a result of exposure to soluble fractalkine 
(Fig. 7A,B). As a variety of cell types could be contributing to the reduction in cytokine production in the retina, 
we assessed cytokine production in isolated rd10 microglia treated with soluble fractalkine. This analysis revealed 
www.nature.com/scientificreports/
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Figure 3. Norgestrel upregulates fractalkine in 661 W cells and C57 explants. (A) Quantification of fractalkine 
fluorescence intensity in 661 W cells treated with 20 μ M Norgestrel or vehicle (DMSO) (N = 6 technical replicates). 
(B) Example images of fractalkine immunofluorescence (red) in 661 W cells treated with Norgestrel or vehicle. 
Scale bar 30 μ m. (C) Densitometry analysis of Western blots for 100 kDa fractalkine in 661 W cells treated with 
20 μ M Norgestrel or vehicle (N = 3 biological replicates). (D) Western blot for fractalkine in 661 W cells following 
Norgestrel treatment. Membrane-bound fractalkine at 100 kDa is highlighted (red box). Total protein level is 
shown alongside. (E) Quantification of fractalkine fluorescence intensity in the ONL of P20 C57 explants cells 
treated with Norgestrel or vehicle (N = 3 explants, n = 4 technical replicates). (F) Example images of fractalkine 
immunofluorescence (green) in the ONL of P20 C57 explants treated with Norgestrel or vehicle. Scale bar 50 μ m.  
(G) Densitometry analysis of Western blots for 100 kDa and 85 kDa fractalkine and CX3CR1 in C57 explants 
cells treated with 20 μ M Norgestrel or vehicle (N = 4 explants). (H) Western blots for fractalkine and CX3CR1 
in P20 C57 explants following Norgestrel treatment. Membrane-bound is observed at 100 kDa (red box) and 
soluble fractalkine at 85 kDa (green box) and CX3CR1 at 45 kDa (blue box). Total protein level is shown alongside. 
Hoechst reveals cell nuclei. Results are presented as mean ± SEM (t-test, *p < 0.05, **p < 0.01, ***p < 0.005).
www.nature.com/scientificreports/
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a similar change in cytokine production in rd10 microglia treated with soluble fractalkine (Fig. 7C,D), highlight-
ing a direct response of microglia to soluble fractalkine in the form of altered cytokine production. Relative levels 
of the 40 cytokines assessed, released by P15 rd10 microglia in vitro (vehicle only), are shown in Fig. 8.
Amongst the variety of cytokines assessed, we found that several cytokines previously implicated in retinal 
degeneration were reduced in microglial cultures following treatment with soluble fractalkine (highlighted with * 
in Figs 7 and 8). This included the following chemokines: MIP1α /CCL3, CXCL10, MIP2/CXCL2, MIP1β /CCL4, 
eotaxin/CCL11, CCL17 and CXCL930,32–35. Levels of cytokines SDF-1 and IFNγ , also believed to play roles in ret-
inal degeneration36–38, were reduced with soluble fractalkine. Amongst the interleukin family, soluble fractalkine 
treatment resulted in reduced release of IL-1α , IL-4, IL-17, IL-1β , IL-7, IL-10, IL-12 and IL-13 from microglia, 
all of which have been previously implicated in retinal degeneration5,32,39–41. These results therefore suggest that 
Norgestrel upregulates the production and release of soluble fractalkine from viable photoreceptors in the dis-
eased retina, which acts on harmful microglia to induce a migratory phenotype and dampen pro-inflammatory 
responses. The role of fractalkine in Norgestrel’s neuroprotective mechanism is summarized with a schematic in 
Fig. 9.
Figure 4. Fractalkine is required for Norgestrel’s neuroprotective effects against rd10 microglia in vitro. 
(A) Example images of fractalkine immunofluorescence (red) in 661 W cells treated with siRNA against 
fractalkine. Scale bar 30 μ m. (B) Western blot showing decreased levels of fractalkine in 661 W cells treated with 
siRNA fract. vs scrambled. Total protein level is shown alongside. (C) Detection of fractalkine mRNA levels by 
RT-PCR in 661 W cells following treatment with scrambled or siRNA targeted to fractalkine. (D) Cell viability 
of 661 W cells following siRNA fract. treatment as assessed by the MTS assay (N = 10 technical replicates). (E) 
Quantification of TUNEL+ 661 W cells pre-treated with a combination of scrambled RNA, siRNA fract., 20 μ 
M Norgestrel or vehicle (DMSO) and in co-culture with rd10 microglia (N = 8 mice for primary culture, n = 6 
technical replicates). (F) Example images of TUNEL+ 661 W cells (green) pre-treated with a combination of 
scrambled RNA, siRNA fract., Norgestrel or vehicle and in co-culture with rd10 microglia. Scale bar 30 μ m.  
Hoechst reveals cell nuclei. Results are presented as mean ± SEM (two-way ANOVA, *p < 0.05, **p < 0.01, 
****p < 0.0001).
www.nature.com/scientificreports/
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Discussion
In this study, we demonstrate the neuroprotective properties of Norgestrel as a modulator of photoreceptor-microglia 
crosstalk in the retina. We have previously shown that rd10 microglia drive neuronal cell death of viable 661 W 
cells in vitro, and treating 661 W cells prior to co-culture reduced microglial-driven cell death7. In the cur-
rent study, we wished to investigate this neuroprotective mechanism further, focusing on signaling pathways 
involved in photoreceptor-microglia crosstalk. Fractalkine-CX3CR1 signaling modulates such crosstalk, 
and is being considered as a potential molecular target for the treatment of RP9. Indeed, we have shown that 
Norgestrel upregulates fractalkine-CX3CR1 signaling in the rd10 retina 1000 fold at the RNA level, coinciding 
with significant preservation of the ONL7. We therefore designed the current study to investigate the mechanisms 
underlying Norgestrel-driven, indirect modulation of microglial activity, with a particular focus on the role of 
fractalkine-CX3CR1 signaling.
We have previously shown that rd10 microglia kill healthy 661 W cells in vitro, suggesting that rd10 microglia 
will drive degeneration of viable photoreceptors in vivo7. To substantiate this claim, we repeated this co-culture 
Figure 5. Fractalkine is required for Norgestrel’s neuroprotective effects against rd10 microglia ex 
vivo. (A) Densitometry analysis of Western blots for 100 kDa and 85 kDa fractalkine and CX3CR1 in rd10 
explants treated with vehicle (DMSO), 100 nM GI254023X (Inhibitor/INH.), 20 μ M Norgestrel (NORG) or 
Norgestrel + GI254023X (N + INH.) (N = 3 explants). (B) Western blots showing reduced levels of soluble 
fractalkine (85 kDa; green box) in the P15 rd10 retina when cleavage is inhibited with 100 nM GI254023X 
(INH.). Levels of CX3CR1 were unaffected. Total protein level is shown below. (C) Quantification of TUNEL 
fluorescence intensity in P15 rd10 explants treated with vehicle (DMSO), 100 nM GI254023X (Inhibitor/INH.), 
20 μ M Norgestrel (NORG) or Norgestrel + GI254023X (N + INH.) (N = 3 explants, n = 4 technical replicates). 
(D) Example images of TUNEL reactivity (green) in the ONL of rd10 explants represented in (C). Scale bar 30 μ m. 
Hoechst reveals cell nuclei. Results are presented as mean ± SEM (t-test, *p < 0.05, **p < 0.01, p*** < 0.005).
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experiment substituting 661 W cells for C57 retinal explants. This confirmed that rd10 microglia drive cell death 
of viable photoreceptors ex vivo, strengthening the hypothesis that rd10 microglia potentiate degeneration in 
the diseased retina (Fig. 1). Pre-treating 661 W cells and C57 explants with Norgestrel prior to co-culture with 
rd10 microglia reduced photoreceptor cell death, highlighting the ability of Norgestrel to prime 661 W cells and 
photoreceptors against potential microglial damage. Potentiation of cell death in the DMSO-treated C57 explant 
co-cultured with rd10 microglia, coincided with an infiltration and increase of microglia in the ONL (Fig. 2). 
Microglia were observed along the outer and inner borders of the C57 retinal explant, in contrast to the presence 
of microglia in the OPL predominantly of the untreated C57 explant. We therefore believe that the source of these 
infiltrating microglia is the rd10 microglia cultured with the explant.
Norgestrel treatment resulted in increased levels of fractalkine in 661 W cells and C57 retinal explants 
(Fig. 3). Western blot analyses revealed bands at 100 kDa and 95 kDa, which represent membrane-bound and 
intra-cellular stores of fractalkine in vesicles respectively18–20. A band at 85 kDa reveals levels of soluble fractalk-
ine19,22. Studies have suggested that premature forms of fractalkine can be observed at 50–70 kDa18,19. Such bands 
were observed in the C57 explant but not in 661 W cells. We identified distinct bands at 40 kDa in both 661 W 
cells and C57 explants. In addition, a prominent band at 30 kDa was observed in C57 explants (Fig. 3H). It is 
possible that these low molecular weight bands at 30 kDa and 40 kDa, are also premature forms of fractalkine or 
perhaps products resulting from the cleavage of membrane-bound fractalkine.
Knockdown of fractalkine in 661 W cells and inhibition of fractalkine cleavage in rd10 retinal explants, 
reduced the protective effects of Norgestrel against microglial damage (Figs 4 and 5). This confirms an essen-
tial role for fractalkine-CX3CR1 signaling in the neuroprotection offered by Norgestrel. When fractalkine was 
knocked down in 661 W cells, Norgestrel’s protective effects against microglia were not completely prevented 
Figure 6. Soluble fractalkine is neuroprotective and modulates microglial migration in rd10 explants.  
(A) Quantification of TUNEL fluorescence intensity in P15 rd10 explants treated with vehicle (0.1% BSA in 1 x PBS) 
or 100ng/ml recombinant soluble fractalkine (N = 4 explants, n = 4 technical replicates). Scale bar 30 μ m.  
(B) Example images of TUNEL reactivity (green) in the ONL of rd10 explants treated with vehicle or soluble 
fractalkine. (C) Example images of microglia (Iba1; red) and activated microglia (CD68; green) in rd10 explants 
treated with vehicle or recombinant soluble fractalkine. Scale bar 50 μ m. (E) Quantification of the number of 
microglia situated in the ONL in rd10 explants treated with vehicle or recombinant soluble fractalkine (N = 4 
explants, n = 4 technical replicates). Hoechst reveals cell nuclei. Results are presented as mean ± SEM (t-test, 
****p < 0.0001).
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(Fig. 4; Scrambled vehicle vs siRNA fract. Norg). This is not surprising as fractalkine was reduced rather than 
absent at the protein and RNA level by siRNA knockdown. Supporting previous observations9,42,43, we have shown 
in the rd10 retina that soluble fractalkine modulates migration of microglia (Fig. 6). We found that addition of 
recombinant soluble fractalkine induced a migratory phenotype in rd10 microglia. Indeed, studies have presented 
similar findings using CX3CR1− /− mice to show that loss of fractalkine signaling reduces motility of both rest-
ing and activated microglia in the retina24. Studies in the brain have documented an anti-inflammatory role for 
fractalkine-CX3CR1 signaling44–46. Here we reveal a role for soluble fractalkine in dampening pro-inflammatory 
phenotypes in rd10 retinal microglia (Fig. 7).
In previous studies, we have demonstrated the direct action of Norgestrel on rd10 microglia, dampening 
pro-inflammatory processes and consequently improving neuronal survival in vitro7. The current work highlights 
an additional aspect to Norgestrel’s actions on microglia, acting indirectly through photoreceptors to alleviate 
harmful microglial activity. In summary, this study highlights a vital aspect to Norgestrel’s neuroprotective prop-
erties, alleviating harmful microglial activity through the modulation of photoreceptor-microglia crosstalk. We 
demonstrate that fractalkine-CX3CR1 signaling plays a critical role in Norgestrel-mediated neuroprotection in 
the rd10 retina, promoting a migratory phenotype in microglia, downregulating the release of pro-inflammatory 
Figure 7. Soluble fractalkine modulates cytokine release in rd10 explants and microglia. (A,B) Relative 
levels of (A) chemokines and cytokines and (B) interleukins in P15 rd10 explants treated with 100 ng/ml soluble 
fractalkine compared to vehicle. Vehicle (0.1% BSA in 1x PBS) for each cytokine is represented by the dotted 
red line at 1 (N = 4 explants, n = 2 technical replicates). (C,D) Relative levels of (C) chemokines and cytokines 
and (D) interleukins in isolated rd10 microglia treated with soluble fractalkine compared to vehicle. Vehicle for 
each cytokine is represented by the dotted red line at 1 (N = 12 retinas, n = 2 technical replicates) (* highlights 
cytokines implicated in retinal degeneration).
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cytokines and consequently increasing photoreceptor survival (Fig. 9). These findings reinforce the prospect of 
Norgestrel as a promising therapeutic for RP.
Methods
Mice. All animals were handled and maintained following the Association for Research in Vision and 
Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research (License Number 
AE19130). Experiments were approved by University College Cork Animal Experimentation Ethics Committee 
and were performed using both male and female homozygous rd10/rd10 mice (B6.CXBI-Pde6brd10/J) and 
C57BL/6 J mice. Mice were supplied by the Biological Services Unit, University College Cork and were humanely 
euthanized by cervical dislocation.
Retinal explant culture. Retinal explants were cultured from P20 C57 and P15 rd10 mice. Eyes were enu-
cleated and transferred to a sterile laminar flow hood. Whole retinas were carefully dissected and placed, pho-
toreceptor side down, on a cell culture insert in R16 medium supplemented with various other compounds13. 
Each explant was cultured in one chamber of a 6-well multi-dish in 1.2 ml of medium with 20 μ M Norgestrel 
(Sigma), 100 ng/ml recombinant mouse soluble fractalkine (R&D systems) or vehicle (DMSO or 0.1% BSA in 
Figure 8. Relative levels of cytokines released by isolated P15 rd10 microglia in vitro. Levels of IL-5, the 
least abundant cytokine detected in media, were set to 1 (N = 12 retinas, n = 2 technical replicates) (* highlights 
cytokines implicated in retinal degeneration).
Figure 9. Schematic summarizing the role of fractalkine-CX3CR1 signaling in Norgestrel-mediated retinal 
neuroprotection. GI254023X is a potent inhibitor of ADAM10, a metalloproteinase responsible for the cleavage 
of membrane-bound fractalkine.
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1x PBS respectively). For experiments using the ADAM10 inhibitor GI254023X (100 nM, Sigma), explants were 
pre-treated with inhibitor or vehicle (DMSO) for 1 h before the addition of Norgestrel or vehicle (DMSO).
Immunohistochemistry on retinal sections. Whole retinal explants were fixed at room temperature in 
4% paraformaldehyde (PFA) for 0.5 h. Following washes, retinas were cryo-protected in 15% sucrose in 1xPBS 
for 1 h, 20% sucrose for 1 h and 30% sucrose overnight, all at 4 °C. Retinas were submerged and frozen in cry-
ochrome (Thermo Scientific, Waltham, US) and sectioned on a cryostat (Leica, Wetzlar, Germany). Sections 
(7 μ m for TUNEL and 20 μ m for IF on microglia) were collected on Superfrost glass slides (Fisher Scientific, 
Waltham, US) and stored at − 80 °C. Sections were blocked and permeabilized with 0.1% Triton X and 5% donkey 
serum in 1xPBS for 30 min and incubated with primary antibody diluted in 5% donkey serum overnight at 4 °C. 
Table 1 lists the details of all primary antibodies used. Following washes, sections were incubated with secondary 
antibody (Alexa Fluor donkey anti-rabbit/rat with either a 488 or 594 fluorescent probe; Molecular Probes &) 
and Hoechst 33342 nuclear stain (1:10,000; ThermoFischer) for 1 h at room temperature. Eliminating the pri-
mary antibody in solution served as a negative control (Supplementary Figure S1). Sections were mounted using 
Mowiol (Sigma) with Dabco anti-fade agent (Sigma).
Immunohistochemistry on cells. Microglia and/or 661 W cells cultured on polylysine-coated coverslips 
in 24 well plates were fixed with 4% PFA for 10 min at room temperature. Cells were blocked and permeabilized 
in 0.1% Triton X and 5% donkey serum in 1xPBS for 10 min and incubated with primary antibody diluted in 5% 
donkey serum overnight at 4 °C. Table 1 lists the details of all primary antibodies used. Following washes, cells 
were incubated with secondary antibody (Alexa Fluor donkey anti-rabbit with either a 488 or 594 fluorescent 
probe) and Hoechst 33342 nuclear stain (1:10,000) for 1 h at room temperature. Eliminating the primary antibody 
in solution served as a negative control. Cells on coverslips were mounted on to glass slides using Mowiol with 
Dabco anti-fade agent.
Microscopy and quantification. Retinal sections and cell preparations were viewed using a Leica DM 
LB2 microscope with Nikon Digital Sight DS-U2 camera, using a 40x objective. Images were taken using the 
software NIS-Elements version 3.0, Nikon, Japan. Immunofluorescence on retinal sections was performed on at 
least three explants of each group. Images were taken and quantification was performed in the central portion of 
the retina. Immunofluorescence on cell preparations was also performed in triplicate. ImageJ software was used 
for quantification. Number of microglia contacting 661 W cells included any microglial cell nucleus overlapping 
with 661 W cell cytoplasm, identified with cone arrestin. Fluorescence intensity measurements of fractalkine in 
661 W cells and C57 explants was performed using ImageJ software as previously described25. An identical size 
box was drawn within the boundaries of each cell or within the ONL and used for measurement of average fluo-
rescence intensity. Confocal micrographs were taken using an Olympus Fluoview FV1000 laser scanning confocal 
microscope, using a 20x objective. Images were taken using the software Olympus Fluoview Ver 4.1a and are 
represented as maximum intensity projections from acquisition of z-stacks. Identical microscope settings were 
used when visualizing specific markers across treatments.
Terminal dUTP Nick-End Labeling (TUNEL) of fragmented DNA. DNA strand breaks in retinal 
explant sections and 661 W cells were detected by terminal dUTP nick end-labeling (TUNEL) on fixed tissue and 
cells. Retinal sections or cells were permeabilized with 0.1% Triton X for 2 min followed by incubation with termi-
nal deoxynucleotidyl transferase (Promega, Wisconsin, US) and fluorescein-12-dUTP (Roche, Risch-Rotkreuz, 
Switzerland) according to manufacturer’s instructions. Nuclei were counterstained with Hoechst 33342 (1:10,000) 
(Sigma). Sections and cells were incubated at 37 °C for 1 h in a humidified chamber and following several washes 
in 1xPBS, were mounted in Mowiol. Sections were viewed under a fluorescence microscope (Leica DM LB2). 
Eliminating the TdT enzyme served as a negative control (Supplementary Figure S1). In co-culture assays, 
TUNEL-positive 661 W cells could easily be distinguished from microglia based on nuclear size and phase con-
trast of cell preparations. Fluorescence intensity measurements of TUNEL in the ONL was performed using 
ImageJ software. An identical size box was drawn within the boundaries of the ONL for each explant and used to 
take five independent measurements, to be averaged.
Culture of cell lines. Experiments were carried out using the mouse 661 W cone photoreceptor-derived cell 
line (passage 25–35), generously provided by Dr Muayyad Al-Ubaidi (Department of Cell Biology, University 
of Oklahoma, Health Sciences Centre, Oklahoma City, OK, USA). This cell line was previously validated by this 
group through real time quantitative polymerase chain reaction (rt-qPCR) analysis for cone specific opsins; 
blue cone opsin (Opn1sw) and red/green opsin (Opn1mw)17. Cells were cultured in Dulbecco’s Modified Eagle’s 
Antibody Supplier Catalogue # Host Dilution Factor
Iba1 Wako 019–19741 Rabbit polyclonal IF 1:500
CD68 AbD Serotec MCA1957GA Rat monoclonal IF 1:500
Cone Arrestin Millipore AB15282 Rabbit polyclonal IF 1:1,000
Fractalkine Abcam AB25088 Rabbit polyclonal IF: 1:1,000 WB 1:1,000
CX3CR1 Abcam AB8021 Rabbit polyclonal WB 1:500
Table 1.  List of antibodies used for Western blotting and immunofluorescence.
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medium (DMEM) (Sigma) supplemented with 10% fetal calf serum (FCS) and 1% penicillin streptomycin (PS) 
and maintained at 37 °C in a humidified 5% CO2 atmosphere. To analyze the effects of Norgestrel (Sigma) on 
661 W cells, cells were seeded in to the appropriate culture vessel and allowed to attach overnight. Cells were 
washed with warmed 1xPBS and complete medium supplemented with 20 μ M Norgestrel or vehicle (DMSO) 
was added.
Western Blotting. 661 W cells were detached using accutase and centrifuged at 1,000 rpm for 5 min. 
661 W cell pellets and whole retinas were homogenized in RIPA buffer (Thermo) containing protease inhibitors 
(Thermo). Lysates were centrifuged at 10,000 rpm at 4 °C for 30 min. Supernatant was stored at − 80 °C. Protein 
concentration was measured using a Bradford assay (Bio-Rad, Hercules, US). 4–15% gradient gels (Bio-Rad) 
were used for SDS-PAGE and proteins were then transferred to a nitrocellulose membrane. 30 μ g of protein was 
loaded per sample. Total protein levels are an accurate way of verifying equal loading47 and so were analyzed using 
REVERT total protein stain (LiCor, Lincoln, US) as per manufacturer’s instructions and imaged on a LiCor scan-
ner in the 700 channel. Membranes were blocked using Odyssey blocking buffer (LiCor) for 30 min and probed 
with fractalkine primary antibody (1:1000, Abcam, Cambridge, UK) or CX3CR1 (1:500, Abcam) in blocking 
buffer and 0.1% Tween 20 for 4 nights at 4 °C. Membranes were washed using TBS-T and probed with rabbit 
800 secondary antibody (LiCor). Membranes were imaged on a LiCor scanner. Blots are representative of three 
biological replicates.
Culture of primary microglial cells. A protocol for isolating and culturing retinal microglia was adapted 
from a previously published protocol48 as previously described7. Culture purity was confirmed by immunoflu-
orescence7. Briefly, retinas were dissected from the eyes of P15 rd10 mice, ensuring minimum contamination 
with vitreous body and retinal pigment epithelium. Six retinas were pooled, cut into small pieces and incubated 
for 40 min at 37 °C in 1 ml 1xPBS with 1 mg/ml collagenase type I (Sigma), 0.3 mg/ml DNase I (Roche, Basel, 
Switzerland), and 0.2 mg/ml hyaluronidase (Sigma). The cell suspension was filtered through a 70-μ m cell strainer 
(Becton Dickinson, Franklin Lakes, US). Cells were washed twice with 10 ml DMEM/10% FCS/1% PS and sus-
pended in 15 ml DMEM/10% FCS/1% PS. To isolate mononuclear cells, the suspension was gently added to 15 ml 
Ficoll paque premium reagent (GE Life Sciences, Buckinghamshire, UK) and centrifuged for 20 min at 2,000 rpm 
without the brake in a Beckmann GS-6R centrifuge. The interphase was removed carefully and washed twice 
with 10 ml DMEM/10% FCS/1% PS. Primary microglia were cultured on polylysine-coated coverslips in 24 well 
plates for 1 day before the addition of 661 W cells, or prior to treating with recombinant mouse soluble fractalkine 
(100 ng/ml, R&D systems) or vehicle (0.1% BSA in 1xPBS) for 24 h. Conditioned media was collected and centri-
fuged at 1,000 rpm for 5 min. Supernatant was stored at − 80 °C.
Co-culture of rd10 microglia with 661 W cells. Primary microglia were cultured on polylysine-coated 
coverslips in 24 well plates for 1 day, and washed with 1xPBS prior to the addition of healthy 661 W cells that 
had been treated with Norgestrel or vehicle (DMSO) in the preceding 24 h. 661 W cells suspended in fresh 
DMEM/10% FCS/1% PS were added to the microglia at a density of 20 × 103 per well. Co-cultures of microglia 
and 661 W cells were left for 24 h before fixation in 4% PFA.
Co-culture of rd10 microglia with C57 explants. C57 P20 retinal explants were cultured in the presence 
of 20 μ M Norgestrel or vehicle for 5 hr and washed with 1xPBS prior to the addition of isolated rd10 P15 retinal 
microglia. Rd10 microglia isolated as described in previous sections were cultured with explants for a further 
19 hr.
Assessment of cell viability in 661 W cells by the MTS assay. Cells seeded overnight (2 × 103 per 
well 96 well plate) were washed three times in 1xPBS before treatment. After 20 h of treatment incubation, 20 μ 
l of MTS solution (Promega) was added to each well and incubated for a further 4 h at 37 °C. Viable cells in the 
presence of phenazine methosulfate (PMS) will reduce the MTS solution to form formazan. Detection and quan-
tification of the formazan crystals is then carried out with a microplate reader (Molecular Device Corporation, 
Sunnyvale, US) at 490 nm. 490 nm readings taken from non-template wells (media and MTS, without cells) were 
deducted from actual cellular readings. A further reading at 650 nm was also taken from all wells and deducted 
from the 490 nm readings to account for any cellular debris. The quantity of formazan product as measured by 
the amount of 490 nm absorbance is directly proportional to the number of living cells in culture. Therefore the 
absorbance of the formazan formed in ‘control cell wells’ was taken as 100% viability.
Total RNA Isolation and quantitative real time polymerase chain reaction (rt-qPCR). Total RNA 
was isolated from whole 661 W cells using RNeasy Mini Kit (Qiagen) following manufacturer’s protocol. Genomic 
DNA was eliminated in 661 W cells using RNase free DNase (Qiagen) and cDNA was subsequently synthesized 
using QuantiTect Reverse Transcription Kit (Qiagen). Rt-qPCR was performed using QuantiTect SYBR Green 
PCR Kit (Qiagen) and 10 ng cDNA/well of a 384 well plate (Starstedt AG & Co.) for 661 W cells. Plates were run 
using the Applied Biosystems 7900HT Fast Real-Time PCR System (Life Technologies Ltd., Carlsbad, US) and 
each set of reactions included both a non-reverse transcription control and a no template sample negative con-
trol. The protocol consisted of a cycling profile of 30 s at 95 °C, 60 s at 60 °C, and 30 s at 72 °C for 40 cycles. Qiagen 
QuantiTect primer assays for fractalkine (QT00128345), actin (QT0095242), GAPDH (QT0165692) and HPRT 
(QT00166768) were used. Melt curve analysis confirmed a single PCR product. Relative changes in gene expres-
sion were quantified using the comparative Ct (Δ Δ Ct) method as described by Livak & Schmittgen49,50. The Ct 
value of the gene of interest was normalized to an average of three endogenous housekeeping genes (Actb, Gapdh 
and Hprt). This was compared to the normalized control sample. Alteration in mRNA expression of genes was 
www.nature.com/scientificreports/
13Scientific RepoRts | 7:43067 | DOI: 10.1038/srep43067
defined as fold difference in the expression level in cells after treatment, relative to that of the control. This is the 
standard method for presenting rt-qPCR data49,50.
siRNA transfection in 661 W cells. Cells were seeded 6 h prior to transfection. Fractalkine GeneSolution 
siRNA (5 nM, Qiagen) and Allstars negative control siRNA (5 nM, Qiagen) were then transfected in to the cells 
using HiPerFect transfection reagent (Qiagen). Cells were transfected for 72 hr before treatment with Norgestrel 
or vehicle for a further 24 hr.
Cytokine proteome profiler array. Rd10 P15 retinal explants and isolated microglia were treated with sol-
uble fractalkine (100 ng/ml) or vehicle (0.1% BSA in 1xPBS) for 24 hr. Explants were homogenized in RIPA buffer 
(Thermo) containing protease inhibitors (Thermo). Lysates were centrifuged at 10,000 rpm at 4 °C for 30 min 
and supernatants stored at − 80 °C. Protein concentration was calculated using the Bradford assay (Biorad). A 
single lysate solution for each treatment (vehicle or soluble fractalkine) contained 300 μ g of protein from three 
explants, using 100 μ g of protein from each explant. For primary microglia, conditioned media from vehicle or 
soluble fractalkine-treated cells was collected. Twelve retinas from six rd10 mice age P15 were used to make the 
primary culture. Media was centrifuged at 1,000 rpm at 4 °C for 5 min to eliminate debris. The proteome profiler 
mouse cytokine array panel A kit (R&D systems) was used to assess the concentration of 40 cytokines in samples 
of interest. As per manufacturers’ instructions, a single membrane with antibodies against 40 cytokines in dupli-
cate, was used per treatment group. Membranes were blocked with the supplied blocking buffer and incubated 
with a solution of explant lysate or microglial conditioned media overnight at 4 °C. Following washes, membranes 
were incubated with IRDye 800CW Streptavidin (1:2,000, LiCor) in blocking buffer for 30 min. Membranes were 
washed and imaged on a LiCor scanner in the 800 channel. Fluorescence intensity was measured using Image 
Studio Lite software. The average intensity of the two duplicate spots per antibody was calculated. Vehicle values 
of each cytokine were set to 1 and the resulting relative values for the treatment group plotted on a bar graph.
Statistical analysis. Values in all graphs represent the mean ± standard error of the mean (SEM) and are 
representative of at least three replicates. Data were statistically analyzed using Student t-test or two-way ANOVA 
with multiple comparisons (Graph Pad, Prism 6) with values of p < 0.05 being considered statistically significant.
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